晚期肝细胞癌的全身化学免疫疗法

Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.

作者信息

Yin Xiao-Yu, Lü Ming-De, Liang Li-Jian, Lai Jia-Ming, Li Dong-Ming, Kuang Ming

机构信息

Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.

出版信息

World J Gastroenterol. 2005 Apr 28;11(16):2526-9. doi: 10.3748/wjg.v11.i16.2526.

DOI:10.3748/wjg.v11.i16.2526

PMID:15832431

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4305648/

Abstract

AIM

To evaluate the therapeutic efficacy of systemic chemo-immunotherapy for advanced hepatocellular carcinoma (HCC).

METHODS

Twenty-six patients with advanced HCC were treated by using systemic chemo-immunotherapy (PIAF regimen), which consisted of cisplatin (20 mg/m2) intravenously daily for 4 consecutive day, doxorubicin (40 mg/m2) intravenously on day 1, 5-fluorouracil (400 mg/m2) intravenously daily for 4 consecutive day, and human recombinant alpha-interferon-2a (5 MU/m2) subcutaneous injection daily for 4 consecutive day. The treatment was repeated every 3 wk, with a maximum of six cycles.

RESULTS

A total of 90 cycles of PIAF treatment were administered, with a mean number of 3.9 cycles per patient. Eight patients received six cycles of treatment (group A), and the remaining 18 were subjected to two to five cycles (group B). There were 0 complete responses, 4 partial responses, 9 static diseases and 13 progressive diseases, with a disease control rate of 50% (13/26). The 1-year survival rate was 24.3%, with a median survival time of 6.0 mo. Group A had a remarkably better survival as compared with group B, the 1- and 2-year survival rates were 62.5% vs 6.1% and 32.3% vs 0%, and a median survival time was 12.5 mo vs 5.0 mo (P = 0.001).

CONCLUSION

Systemic chemo-immunotherapy using PIAF regimen represented an effective treatment and could improve the survival rate and prolong the survival time in selected patients with advanced HCC.

摘要

目的

评估全身化疗免疫疗法对晚期肝细胞癌（HCC）的治疗效果。

方法

26例晚期HCC患者接受全身化疗免疫疗法（PIAF方案）治疗，该方案包括顺铂（20mg/m²）静脉滴注，每日1次，连续4天；阿霉素（40mg/m²）于第1天静脉滴注；5-氟尿嘧啶（400mg/m²）静脉滴注，每日1次，连续4天；重组人α-干扰素-2a（5MU/m²）皮下注射，每日1次，连续4天。每3周重复治疗1次，最多进行6个周期。

结果

共进行了90个周期的PIAF治疗，每位患者平均接受3.9个周期。8例患者接受6个周期治疗（A组），其余18例接受2至5个周期治疗（B组）。完全缓解0例，部分缓解4例，病情稳定9例，病情进展13例，疾病控制率为50%（13/26）。1年生存率为 24.3%，中位生存时间为6.0个月。A组的生存率明显优于B组，1年和2年生存率分别为62.5%对6.1%，32.3%对0%，中位生存时间为12.5个月对5.0个月（P=0.001）。